- Report
- October 2024
- 184 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 270 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- June 2020
- 753 Pages
Global
From €3003EUR$3,300USD£2,575GBP
- Report
- February 2024
- 245 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- August 2022
- 240 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- January 2022
- 224 Pages
Global
From €6325EUR$6,950USD£5,423GBP
- Report
- April 2024
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- February 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- January 2022
- 110 Pages
Global
From €4323EUR$4,750USD£3,706GBP
Entrectinib is a type of targeted therapy used to treat certain types of cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. Entrectinib is used to treat non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other types of solid tumors. It is approved for use in adults and children who have tumors with certain genetic mutations.
Entrectinib is a relatively new drug, and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, including breast cancer, colorectal cancer, and pancreatic cancer.
Entrectinib is marketed by several pharmaceutical companies, including Roche, AstraZeneca, and Novartis. It is also being developed by several biotechnology companies, such as Ignyta, Inc., and Daiichi Sankyo. Show Less Read more
